<DOC>
	<DOC>NCT01052298</DOC>
	<brief_summary>Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with mild to moderate COPD (stage I-II according to GOLD Criteria).</brief_summary>
	<brief_title>Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Adult patients with COPD (Stage I or II according to the GOLD Classification), 35 years of age or older Airway obstruction with a postbronchodilator Forced Expiratory Volume (FEV1) &gt; or equal 50% of predicted normal and a postbronchodilator FEV1 / Forced Vital Capacity (FVC) &lt; 70%. Current or exsmokers with a smoking history of more than 10 packyears Body mass index (BMI) between 18 and 33 kg/m2 Written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures Significant disease other than COPD as bronchial asthma, cystic fibrosis or clinically evident bronchiectasis Total blood eosinophil count &gt;/=600/mm3. Thoracotomy with pulmonary resection Regular use of daytime oxygen therapy Completion of a pulmonary rehabilitation program in the six weeks prior to the prestudy examination or current participation in a rehabilitation program Hypersensitivity to the investigational drug or to other quinolones and/or to inactive constituents of the inhalation powder Hypersensitivity of the bronchial system to inhalation of nebulized drugs or saline solution Acute pulmonary exacerbation Patients with a history of severe allergies, nonallergic drug reactions, or multiple drug allergies Concomitant inhalative therapy with antibiotics and/or concomitant systemic therapy with fluoroquinolones Oral betaadrenergics, beta blockers Long acting anticholinergics within 2 weeks prior to prestudy examination Inhaled or oral steroids Methylxanthines: 24hour washout of shortacting theophylline and 48hour washout of longacting theophylline prior to prestudy examination Antihistamines, antileukotrienes prescribed for asthma oral cromolyn sodium or oral nedocromil sodium</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Ciprofloxacin</keyword>
	<keyword>Inhalation</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>COPD</keyword>
</DOC>